ReviewNature reviews. Nephrology2021
Non-invasive molecular imaging of kidney diseases.
Review in Nature reviews. Nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 79 citations in OpenAlex.
- Self-Amplified Activatable Fluorescent Probe for Early Diagnosis of Acute Kidney Injury and High-Throughput Screening of Natural Protectants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Contrast-sparing CT using renal-clearable gold nanoclusters for early spatial mapping of renal dysfunction.Science advances · 2026Article
- Evaluation of IVIM-MRI biomarkers for microvascular dysfunction and prognosis in juvenile osteochondritis dissecans of the knee: a single-center study.Journal of orthopaedic surgery and research · 2026Article
- Tubular MAG3 Extraction Rate is a Predictor of Short-Term and Long-Term Outcome After Kidney Transplantation: A Prospective Observational Study.Clinical nuclear medicine · 2026Observational
- Artificial intelligence with deep convolutional neural network-based clinical decision-making on kidney Oncology using multimodal imaging.Scientific reports · 2026Article
- Enhancing therapeutic strategies and drug development for patients with kidney disease.Expert opinion on drug safety · 2026Review
- Non-invasive assessment techniques for renal fibrosis: advances and perspectives.Renal failure · 2025Review
- Molecular imaging of stem cell therapies in ischemic stroke.European journal of nuclear medicine and molecular imaging · 2025Review
- Pharmacokinetic Characterization of Single-Stranded DNA in Murine Models Using High-Specific-ActivityACS omega · 2025Article
- Nuclear Insights in Nephrology: Echoes from 1975.Indian pediatrics · 2025Article
- A noninvasive model for chronic kidney disease screening and common pathological type identification from retinal images.Nature communications · 2025Article
- Dynamic, multiphase magnetic resonance imaging of in vivo physiological processes with long-lived hyperpolarizedScience advances · 2025Article
- Harnessing the power of nanoagents in acute kidney injury: A versatile platform for imaging and treatment.Coordination chemistry reviews · 2025Article
- Dynamic Tracking ofMolecular pharmaceutics · 2025Article
- Collagen formation, function and role in kidney disease.Nature reviews. Nephrology · 2025Review
- Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging.Journal of translational medicine · 2025Review
- Advances in Diagnosis and Treatment of Inherited Kidney Diseases in Children.Kidney diseases (Basel, Switzerland) · 2024Review
- Non-invasive assessment of IgA nephropathy severity with [Clinical kidney journal · 2024Article
- Single-point mutated lanmodulin as a high-performance MRI contrast agent for vascular and kidney imaging.Nature communications · 2024Article
- Imaging kidney inflammation using an oxidatively activated MRI probe.Kidney international · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
In nephrology, differential diagnosis or assessment of disease activity largely relies on the analysis of glomerular filtration rate, urinary sediment, proteinuria and tissue obtained through invasive kidney biopsies. However, currently available non-invasive functional parameters, and most serum and urine biomarkers, cannot capture intrarenal molecular disease processes specifically. Moreover, although histopathological analyses of kidney biopsy samples enable the visualization of pathological morphological and molecular alterations, they only provide information about a small part of the kidney and do not allow longitudinal monitoring. These limitations not only hinder understanding of the dynamics of specific disease processes in the kidney, but also limit the targeting of treatments to active phases of disease and the development of novel targeted therapies. Molecular imaging enables non-invasive and quantitative assessment of physiological or pathological processes by combining imaging technologies with specific molecular probes. Here, we discuss current preclinical and clinical molecular imaging approaches in nephrology. Non-invasive visualization of the kidneys through molecular imaging can be used to detect and longitudinally monitor disease activity and can therefore provide companion diagnostics to guide clinical trials, as well as the safe and effective use of drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.